Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Treatment effect by nasal polyps, aspirin/NSAID intolerance, and GERD

被引：0

作者：

Albers, F. C. ^{[1
]}

Liu, M. C. ^{[2
,3
,4
]}

Chipps, B. E. ^{[5
]}

Chapman, K. R. ^{[6
,7
]}

Munoz, X. ^{[8
]}

Bergna, M. A. ^{[9
]}

Devouassoux, G. ^{[10
]}

Price, R. G. ^{[11
]}

Galkin, D., V ^{[1
]}

机构：

[1] GSK, Resp Med Franchise, Res Triangle Pk, NC USA

[2] Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol, Baltimore, MD USA

[3] Johns Hopkins Asthma & Allergy Ctr, Div Pulm, Baltimore, MD USA

[4] Johns Hopkins Asthma & Allergy Ctr, Div Crit Care Med, Baltimore, MD USA

[5] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA

[6] UHN, Asthma & Airway Ctr, Toronto, ON, Canada

[7] Univ Toronto, Toronto, ON, Canada

[8] Hosp Univ Vall dHebron, Dept Pneumol, Barcelona, Spain

[9] CEMER, Resp Res, Buenos Aires, DF, Argentina

[10] Ucb Lyon 1, Ea7426, Hosp Civils Lyon, Serv Pneumol,Hop Croix Rousse, Lyon, France

[11] GSK, Biostat, Stevenage, Herts, England

来源：

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

LBPD1779

引用

页码：363 / 363

页数：1